Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Study sponsor: ArriVent BioPharma, Inc. · AVBP
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-02Estimated
Enrollment · participants480Estimated
Source updated2026-11-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.